The startup develops radiation sensitizer drugs that enhance the effectiveness of existing anticancer therapies by improving tumor response to chemotherapy. By commercializing research from both domestic and international cancer studies, the company provides patients with safer and more effective treatment options during their chemotherapy regimens.
Funding
$6.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer patients undergoing chemotherapy experience limited tumor response and significant side effects, highlighting the need for therapies that can enhance the efficacy of chemotherapy while minimizing harm to healthy tissues. Existing anticancer treatments often fail to completely eradicate tumors, leading to recurrence and reduced survival rates.
Solution
The startup is developing radiation sensitizer drugs designed to improve the effectiveness of existing anticancer therapies. These drugs aim to enhance tumor response to chemotherapy, potentially leading to better patient outcomes. By selectively targeting tumor cells, the radiation sensitizers increase their susceptibility to chemotherapy, thereby maximizing the treatment's impact on cancerous tissue while sparing healthy cells from excessive damage. This approach seeks to provide patients with safer and more effective treatment options during their chemotherapy regimens, ultimately improving their quality of life and chances of recovery.
Target Audience
The primary target audience includes cancer patients undergoing chemotherapy, oncologists, and hospitals seeking to improve treatment outcomes.
Features
- Radiation sensitizer drugs designed to enhance tumor response to chemotherapy.
- Aims to improve the effectiveness of existing anticancer therapies.
- Seeks to provide safer and more effective treatment options during chemotherapy regimens.